Robot model
Hugo RAS
Medtronic (NYSE: MDT; founded 1949 in Minneapolis, with legal headquarters in Dublin) makes the Hugo robotic-assisted surgery system, the late-market…
- Manufacturer
- Medtronic
- Form factor
- surgical
- Maturity
- commercial
- Lifecycle
- active
- Deployments
- 3
- Website
- news.medtronic.com ↗
Overview
Medtronic (NYSE: MDT; founded 1949 in Minneapolis, with legal headquarters in Dublin) makes the Hugo robotic-assisted surgery system, the late-market big-medtech challenger to Intuitive's da Vinci. Hugo is a modular multi-port teleoperated platform that received its European CE mark for urologic and gynecologic procedures on October 11, 2021, and, in the key regulatory milestone, US FDA clearance on December 3, 2025 for urologic procedures only, including prostatectomy, nephrectomy, and cystectomy, backed by the Expand URO investigational-device-exemption trial of 137 patients that met its primary safety and efficacy endpoints and was presented at AUA 2025. General-surgery and gynecologic US indications are planned submissions but are not yet cleared. The registry records Hugo at commercial maturity: it has been CE-marked and commercially used outside the US across more than 30 countries since 2021 and is now US-cleared for urology and entering US rollout. Medtronic discloses no specific system installed-base count, citing only tens of thousands of procedures across 30-plus countries, so the unit count is left as an honest absence rather than invented. On AI substance, Hugo is a master-slave teleoperated system whose Touch Surgery digital and video ecosystem is analytics and recording rather than autonomy, with no verified shipped intraoperative AI guidance.
Verified vs. claimed
- Maturity stage
- commercial(Commercially deployed with revenue-generating operations.)
- Verified deployments
- 3 deployments on file
- Sources on file
- 4 sources, view all
Key facts
FDA clearance (verified)
Expansion filing (pending)
VVC flag
Subprocessors
Specs
Notes
Products
Form Factor
Fda clearance
Clearance body
Procedure types
Data & sources
Press releases
2
News coverage
1
Web sources
1
4 sources backing this record.View all →
Availability and pricing
- Availability
- Not sold (internal use)
- Price
- Not publicly disclosed
- Units in field
- Not disclosed
- Sales model
- Not disclosed
- Lead time
- Not disclosed
Pricing
No verified price is on record for Hugo RAS. Physical-AI systems are often sold through enterprise contracts or operated as a service rather than at a public list price.
Deployments (3)
- Hugo RAS at United Statesoperational
The Hugo RAS system received FDA clearance in the United States in December 2023, according to a Medtronic announcement.
- Hugo RAS at Dublinoperational
Medtronic Hugo RAS system deployed at hospitals in Europe and emerging markets for minimally invasive surgery.
- Hugo RAS at European Unionoperational
Medtronic received CE Mark approval for the Hugo robotic-assisted surgery system in October 2021, enabling its commercial availability in the European Union.
Hugo RAS on the deployment map
Where Hugo RAS is verified operating. Explore the deployment map by place and type.
Recent activity
Every change to this record is dated, sourced, and independently verified where marked.
- Verified media addedVerifiedJun 8, 2026
Medtronic Hugo™ RAS System — Product Animation
- Verified media addedVerifiedJun 5, 2026
Medtronic Hugo RAS product animation
- Verified media addedVerifiedJun 5, 2026
Medtronic Hugo RAS first patient procedure
- Verified media addedVerifiedJun 4, 2026
The Medtronic Hugo RAS system is here
- Record createdJun 3, 2026
Added to the verified registry
Deployment-verified media (3)
Medtronic's product animation of its Hugo RAS system, showing the modular arm-carts and open console. The animation depicts the system, not an autonomous capability; the arms are surgeon-driven.
From deployment: Dublin
Medtronic's footage of a first patient procedure on its Hugo RAS robotic-assisted surgery system. The surgeon teleoperates from a master console; the system is never autonomous.
From deployment: Dublin
Medtronic's introduction of its Hugo RAS robotic-assisted surgery system. Hugo is teleoperated by a surgeon from a console; its US FDA clearance covers urologic procedures.
From deployment: Dublin
Supply chain (1)
Sensors
- Karl Storz SE & Co. KG3D vision system / TIPCAM 1 S 3D video endoscope (IMAGE1 S platform)supplies
Suppliers appear here when verified with at least two strong sources (maker-official / IR / regulatory / standards-body / verified tier-2). Sources are append-only; corrections add new sources rather than rewrite history.
Regulatory filings (2)
- fda_de_novofda de novo · us_fdacleared2025-12-01
Applicant: Medtronic
- K250725fda 510k · us_fdagranted2025-03-10
Applicant: Medtronic
Safety record
No incidents on record for Hugo RAS.
Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.
Sources (4)
- https://news.medtronic.com/2025-12-03-Medtronic-announces-FDA-clearance-of-Hugo-TM-robotic-assisted-surgery-system-for-urologic-surgical-procedures
- https://www.urologytimes.com/view/hugo-robot-assisted-surgery-system-launches-on-us-market
- https://news.medtronic.com/2026-06-03-Medtronic-submits-510-k-filings-to-expand-Hugo-TM-robotic-assisted-surgery-system-into-general-and-gynecologic-specialties-in-the-United-States
- https://www.medtechdive.com/news/medtronic-seeks-clearance-for-hugo-surgical-robot-in-more-indications/821969/
Compare Hugo RAS
Common questions
- What is Hugo RAS?
- Medtronic (NYSE: MDT; founded 1949 in Minneapolis, with legal headquarters in Dublin) makes the Hugo robotic-assisted surgery system, the late-market big-medtech challenger to Intuitive's da Vinci. Hugo is a modular multi-port teleoperated platform that received its European CE mark for urologic and gynecologic procedures on October 11, 2021, and, in the key regulatory milestone, US FDA clearance on December 3, 2025 for urologic procedures only, including prostatectomy, nephrectomy, and cystectomy, backed by the Expand URO investigational-device-exemption trial of 137 patients that met its primary safety and efficacy endpoints and was presented at AUA 2025. General-surgery and gynecologic US indications are planned submissions but are not yet cleared. The registry records Hugo at commercial maturity: it has been CE-marked and commercially used outside the US across more than 30 countries since 2021 and is now US-cleared for urology and entering US rollout. Medtronic discloses no specific system installed-base count, citing only tens of thousands of procedures across 30-plus countries, so the unit count is left as an honest absence rather than invented. On AI substance, Hugo is a master-slave teleoperated system whose Touch Surgery digital and video ecosystem is analytics and recording rather than autonomy, with no verified shipped intraoperative AI guidance.
- How much does Hugo RAS cost?
- Hugo RAS's price is not publicly disclosed. DEPLOY has no verified price on record for Hugo RAS from Medtronic. Physical-AI systems like this are often sold through enterprise contracts or operated as a service rather than at a public list price; check the manufacturer for the latest.
- Is Hugo RAS actually deployed in the real world?
- Yes. Hugo RAS is independently verified in real-world operation on the DEPLOY registry, confirmed at named deployment sites with primary sources: not a concept, render, or demo-only.
- Is Hugo RAS autonomous or teleoperated?
- Not verified as fully autonomous. Hugo RAS's capabilities on the DEPLOY registry are recorded as teleoperated-assisted, demonstrated-only, or vendor claims (Assists surgery), not independently confirmed to run without a human in the loop.
- Who makes Hugo RAS?
- Hugo RAS is made by Medtronic, based in Dublin, Ireland, founded in 1949.
- Where is Hugo RAS deployed?
- 3 verified deployments of Hugo RAS are on the DEPLOY registry, including at United States, Dublin, European Union.
- Can you buy Hugo RAS?
- Hugo RAS is in commercial deployment and is sold to operators; contact the manufacturer to buy, and see the pricing section for any recorded price.
- Is Hugo RAS FDA cleared?
- Hugo RAS has 2 regulatory records on the DEPLOY registry: FDA De Novo authorization, cleared; FDA 510(k) clearance (K250725), granted. See the Regulatory filings section for each agency source.
- What are alternatives to Hugo RAS?
- On the DEPLOY registry, comparable surgical robots to Hugo RAS include Toumai, da Vinci (and Ion), Epione, Mako.
- How does Hugo RAS compare to Toumai?
- Hugo RAS and Toumai (MicroPort MedBot · 8 deployments) are both surgical robots on the DEPLOY registry. Hugo RAS has 3 verified deployments on record. Compare both records for specs, safety, deployments, and verified-vs-claimed autonomy.
- Is Hugo RAS a top surgical?
- On DEPLOY's intelligence score, which blends verified deployments, safety, adoption, media, and IP signals, Hugo RAS ranks in roughly the top 5% of surgical models tracked by the registry.
- What is Hugo RAS's maturity stage?
- Hugo RAS is at the commercial stage on the DEPLOY maturity ladder (research, prototype, pilot, commercial, production). Commercial stage means production-grade deployments are operating at named customer sites.
- Is Hugo RAS safe?
- Hugo RAS has no incidents on record in the DEPLOY registry. This does not constitute a safety guarantee; it reflects the incidents DEPLOY has tracked and verified to date.
- How does Medtronic Hugo RAS compare to da Vinci?
- Peer-reviewed studies show no significant differences in hospital stay length, blood loss, or complication rates between Hugo RAS and da Vinci Xi. Da Vinci has shorter docking and console times. Hugo RAS is Medtronic's challenger to Intuitive's da Vinci dominance, with a modular design and open architecture. Da Vinci remains the market leader with a much larger installed base.
Methodology: Verified · 4 sources (2 primary) · last reviewed 2026-07-12
Verification posture
Verified
High confidence
Review state
Stable
Last reviewed 2026-07-12
Maturity + lifecycle
Maturity stage: commercial
Lifecycle: active
Architectural position
Cohort: surgical
Sources by quality tier
- 2
- primary-company-ir
- Company IR disclosure
- 1
- unclassified
- Unclassified source
- 1
- secondary-trade-publication
- Trade publication
The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.
Methodology surface for Hugo RAS.Recent coverage
Hugo RAS in third-party press
Attention vs reality over time
Media mentions per month (area) against verified deployment events (dots). A press spike over a flat deployment line is the hype gap, drawn over time.
In the press
Recent coverage mentioning Hugo RAS from third-party publications. Automatically surfaced; not part of the verified registry record.
Pacemaker manufacturer Medtronic warns patients cybercrooks may have swiped health data
Company that also makes insulin pumps and other devices tells users what was exposed months after ShinyHunters attack
Medtronic's Hugo surgical robot earns FDA clearance
Medtronic Hugo surgical robot earned FDA clearance for additional indication.
After Medtronic Exit, Nehme Charts A Staged Regulatory Path For Soft Robotics With Morph - Citeline News & Insights
<a…
Former Medtronic CCO Torod Neptune launches advisory firm
Former Medtronic Chief Communications Officer Torod Neptune has formed an advisory firm, Neptune & Company. Led by Neptune as founder and managing partner, the firm has not yet…
5 robotic surgery trends to watch in 2026
MedTech Dive: Soft tissue robotic systems expanding into new specialties. Medtronic Hugo competition with Intuitive. Distalmotion Dexter gaining traction. ASC adoption growing.
FDA authorizes more devices in 2026 but it's taking longer
FDA authorized more AI-enabled devices in first half of 2026 but average time to clearance increased by 7-8 days. Average ~156 days to decision.
FDA AI-Enabled Medical Devices List - Updated 2026
FDA's AI-Enabled Medical Device List identifying AI-enabled devices authorized for marketing in the US. Record 295 clearances in 2025.
Medtronic Bets on Ablation, Robotics, and Hypertension - Yahoo Finance
<a…
Medtronic Bets on Ablation, Robotics, and Hypertension - Zacks Investment Research
<a…
Acknowledge Medtronic: Firm Is Ramping Up Robotics Offerings - Medical Device and Diagnostic industry
<a…
Medtronic Advances Hugo Robotic Surgery Platform with Key FDA Filings and Product Approvals
Medtronic announced several regulatory milestones for its Hugo robotic-assisted surgery platform, including FDA submissions for general and gynecologic surgery indications and the…
Medtronic Posts Strongest Revenue Growth in a Decade, Driven by Cardiovascular and Surgical Businesses
Medtronic reported robust fiscal 2026 results, fueled by strong growth in cardiovascular, medical surgical, and diabetes technologies, while advancing key product launches,…
Machine-readable surfaces
- Markdown mirror: /models/medtronic-hugo.md
- JSON-LD: embedded in this page’s head
- REST API: /v1/models/3e170eb2-145b-41a2-88d0-8ff93a5f4e78
- Revision history: /models/medtronic-hugo/history
- Data documentation: /data
- Query this programmatically: Deploy MCP
Buyer-facing pricing: deploy.report/price/medtronic-hugo
Video
Reality vs attention
Hugo RAS draws attention at the 94th percentile but verifies reality at the 84th percentile among surgical robots. Hype Gap +9.9, 10th widest among surgical robots.
6-month trend
Analysis
Strong recent media coverage and press activity. Thin deployment record; scale validation still in progress.
Signal flags
Dimension breakdown
Verified signal
Attention (reach, not merit)
DEPLOY Intelligence scores are computed from verified registry data: confirmed deployments, disclosed funding rounds, regulatory filings, active job listings, video viewership, and press coverage. Confidence ratings reflect data availability. Scores update nightly.
DEPLOY Indices — verified vs claimed
Last computed: Jul 18, 2026